Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Director Jason Aryeh bought 750 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was acquired at an average cost of $87.01 per share, for a total transaction of $65,257.50. Following the acquisition, the director now directly owns 67,203 shares of the company’s stock, valued at $5,847,333.03. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Jason Aryeh also recently made the following trade(s):

  • On Monday, August 5th, Jason Aryeh purchased 746 shares of Ligand Pharmaceuticals stock. The stock was purchased at an average price of $90.01 per share, for a total transaction of $67,147.46.
  • On Monday, July 29th, Jason Aryeh purchased 250 shares of Ligand Pharmaceuticals stock. The stock was purchased at an average price of $106.01 per share, for a total transaction of $26,502.50.
  • On Wednesday, July 31st, Jason Aryeh purchased 4,004 shares of Ligand Pharmaceuticals stock. The stock was purchased at an average price of $99.22 per share, for a total transaction of $397,276.88.
  • On Tuesday, June 11th, Jason Aryeh purchased 250 shares of Ligand Pharmaceuticals stock. The stock was purchased at an average price of $107.01 per share, for a total transaction of $26,752.50.

Shares of NASDAQ:LGND traded down $1.78 during trading hours on Friday, hitting $87.72. The stock had a trading volume of 276,398 shares, compared to its average volume of 336,546. The stock’s fifty day simple moving average is $96.69 and its 200 day simple moving average is $112.93. Ligand Pharmaceuticals Inc. has a 1-year low of $85.87 and a 1-year high of $278.62. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of 13.97, a PEG ratio of 1.96 and a beta of 1.30. The company has a debt-to-equity ratio of 0.61, a quick ratio of 13.15 and a current ratio of 13.23.

Ligand Pharmaceuticals (NASDAQ:LGND) last announced its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.38 by $0.30. Ligand Pharmaceuticals had a net margin of 389.58% and a return on equity of 11.24%. The company had revenue of $24.99 million for the quarter, compared to analyst estimates of $21.01 million. During the same quarter last year, the business earned $2.59 earnings per share. Ligand Pharmaceuticals’s revenue was down 72.2% compared to the same quarter last year. As a group, research analysts anticipate that Ligand Pharmaceuticals Inc. will post 2.28 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of LGND. Victory Capital Management Inc. increased its stake in shares of Ligand Pharmaceuticals by 39.6% during the first quarter. Victory Capital Management Inc. now owns 655,690 shares of the biotechnology company’s stock valued at $82,428,000 after acquiring an additional 186,090 shares during the period. Janus Henderson Group PLC increased its stake in shares of Ligand Pharmaceuticals by 11.4% during the second quarter. Janus Henderson Group PLC now owns 1,542,670 shares of the biotechnology company’s stock valued at $176,096,000 after acquiring an additional 157,604 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Ligand Pharmaceuticals by 37.7% during the first quarter. The Manufacturers Life Insurance Company now owns 557,512 shares of the biotechnology company’s stock valued at $70,085,000 after acquiring an additional 152,649 shares during the period. Telemark Asset Management LLC acquired a new position in shares of Ligand Pharmaceuticals during the second quarter valued at approximately $17,123,000. Finally, Elk Creek Partners LLC increased its stake in shares of Ligand Pharmaceuticals by 128.1% during the first quarter. Elk Creek Partners LLC now owns 209,823 shares of the biotechnology company’s stock valued at $26,377,000 after acquiring an additional 117,839 shares during the period.

LGND has been the topic of several analyst reports. BidaskClub lowered shares of Ligand Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, August 30th. Barclays dropped their price target on shares of Ligand Pharmaceuticals from $131.00 to $110.00 and set an “equal weight” rating on the stock in a research note on Monday, August 5th. Argus set a $140.00 price target on shares of Ligand Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, June 10th. ValuEngine lowered shares of Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Finally, Zacks Investment Research lowered shares of Ligand Pharmaceuticals from a “hold” rating to a “strong sell” rating and set a $95.00 price target on the stock. in a research note on Thursday, August 8th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $147.80.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.

Featured Article: Trading Strategy Methods and Types

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.